Aster Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-1,578
Closed -$380K – 1144
2026
Q2
$380K Buy
1,578
+1,438
+1,027% +$315K 0.08% 313
2026
Q1
$17.4K Sell
140
-37
-21% -$6.47K 0.01% 570
2025
Q4
$30.1K Sell
177
-155
-47% -$23.8K 0.01% 545
2025
Q3
$43.8K Sell
332
-105
-24% -$12.6K 0.02% 522
2025
Q2
$46.4K Sell
437
-10,936
-96% -$1.19M 0.01% 614
2025
Q1
$1.63M Buy
+11,373
New +$1.48M 0.3% 79

Other funds holding JAZZ

Aster Capital Management's JAZZ Position: Q3 2026 in Review

Aster Capital Management sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2026, closing a stake of 1,578 shares — an estimated $380K sold.

Aster Capital Management first reported a position in JAZZ in Q1 2025 and held it in 6 quarters. The position peaked at $1.63M in Q1 2025. 670 funds tracked by Wall St. Rank hold JAZZ as of Q3 2026.

  • Aster Capital Management reported no remaining Jazz Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • Aster Capital Management sold 1,578 Jazz Pharmaceuticals shares in Q3 2026, an estimated $380K.
  • Aster Capital Management first reported a position in Jazz Pharmaceuticals in Q1 2025 and held it in 6 quarters.
  • Aster Capital Management's Jazz Pharmaceuticals position peaked at $1.63M in Q1 2025.
  • 670 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2026.

Based on Aster Capital Management's 13F filing for Q3 2026, filed 12 Nov 2026.